NovaBridge Biosciences ADRNBP
Price$1.34

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Dec 2025
Net Income -$46.3MTTM through 31 Dec 2025
Free Cash Flow -$20.6MTTM through 31 Dec 2025

Margins

Current

Returns

-20.0%ROE
-19.4%ROA

Balance Sheet Health

Debt / Equity0.13x
Current Ratio8.09x
Net Debt-$207.7Mnet cash position
Cash & Equivalents$210.6M

Quality Metrics

Altman Z-Score-3.75
Piotroski F-Score1 / 9
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'20'21'22'23
FY2023: $27.6M
Diluted EPS-$0.21TTM
'19'20'21'22'23'24'25
FY2025: $-0.21

Dividend

No dividend

Capital Allocation

R&D Spend$62.9M

Segment Performance

SegmentRevenueYoYOutlook
Oncology$0
View details

Advancing givastomig toward a potential registrational Phase 3 trial as early as Q4 2026.

Ophthalmology$0
View details

VIS-101 is anticipated to be Phase 3-ready in late 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.